

# Josh Levitsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1210150/publications.pdf>

Version: 2024-02-01

170  
papers

7,358  
citations

53794

45  
h-index

64796

79  
g-index

188  
all docs

188  
docs citations

188  
times ranked

7234  
citing authors

#	ARTICLE	IF	CITATIONS
1	CAQ Corner: Basic concepts of transplant immunology. Liver Transplantation, 2023, 29, 331-339.	2.4	0
2	Prediction of Liver Transplant Rejection With a Biologically Relevant Gene Expression Signature. Transplantation, 2022, 106, 1004-1011.	1.0	11
3	Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients. American Journal of Transplantation, 2022, 22, 532-540.	4.7	31
4	One-Year Outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. Kidney International Reports, 2022, 7, 241-250.	0.8	12
5	Not everything that counts can be counted: Tracking long-term outcomes in pediatric liver transplant recipients. American Journal of Transplantation, 2022, 22, 1182-1190.	4.7	5
6	Biomarkers of rejection in liver transplantation. Current Opinion in Organ Transplantation, 2022, 27, 154-158.	1.6	13
7	The Blood Proteoform Atlas: A reference map of proteoforms in human hematopoietic cells. Science, 2022, 375, 411-418.	12.6	64
8	Poor Practitioner Adherence to Clinical Tobacco Use Guidelines in Liver Transplant Recipients. Transplantation Direct, 2022, 8, e1288.	1.6	4
9	The answer at our fingertips: Volume status in cirrhosis determined by machine learning and pulse oximeter waveform. Physiological Reports, 2022, 10, e15223.	1.7	2
10	THE CONTINUED IMPACT OF ACUTE REJECTION IN THE LAST DECADE OF LIVER TRANSPLANTATION. , 2022, , .		1
11	Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology, 2022, 76, 1862-1879.	7.3	27
12	The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation, 2021, 21, 21-31.	4.7	28
13	Harnessing T cell exhaustion to improve solid organ transplant outcomes. American Journal of Transplantation, 2021, 21, 1660-1661.	4.7	2
14	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. Human Immunology, 2021, 82, 81-88.	2.4	4
15	Advances in Rejection Management. Clinics in Liver Disease, 2021, 25, 53-72.	2.1	3
16	Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. Transplantation, 2021, Publish Ahead of Print, .	1.0	3
17	Ethical Issues When Considering Liver Donor Versus Deceased Donor Liver Transplantation. Clinical Liver Disease, 2021, 17, 71-74.	2.1	3
18	Interest in Immunosuppression Withdrawal among Liver Transplant and Autoimmune Hepatitis Patients. Gastroenterology Insights, 2021, 12, 147-154.	1.2	0

#	ARTICLE	IF	CITATIONS
19	An Unusual Cause of Acute Pancreatitis in a Liver Transplant Recipient. <i>Transplantation Direct</i> , 2021, 7, e694.	1.6	0
20	Erythropoietin administration expands regulatory T cells in patients with autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2021, 119, 102629.	6.5	8
21	Long-term mortality risk stratification of liver transplant recipients: real-time application of deep learning algorithms on longitudinal data. <i>The Lancet Digital Health</i> , 2021, 3, e295-e305.	12.3	41
22	Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. <i>Seminars in Liver Disease</i> , 2021, 41, 308-320.	3.6	0
23	Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study. <i>Hepatology</i> , 2021, 74, 926-936.	7.3	19
24	Mission accomplished? Early data from the simultaneous liver-kidney transplantation allocation policy. <i>American Journal of Transplantation</i> , 2021, 21, 3513-3515.	4.7	1
25	Comanagement With Nephrologist Care Is Associated With Fewer Cardiovascular Events Among Liver Transplant Recipients With Chronic Kidney Disease. <i>Transplantation Direct</i> , 2021, 7, e766.	1.6	5
26	Donor quality of life after living donor liver transplantation: a review of the literature. <i>Digestive Medicine Research</i> , 2021, 4, 49-49.	0.2	5
27	Profiling the liver graft. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 17-22.	1.6	3
28	When evidence is lacking: a mixed-methods approach for the development of practice guidance in liver transplantation. <i>Gastroenterology Report</i> , 2021, 9, 22-30.	1.3	1
29	Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 797-807.	4.7	28
30	Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. <i>Journal of Hepatology</i> , 2020, 72, 481-488.	3.7	93
31	MELD-Na: Glomerular Filtration Rate and Mortality on Liver Transplant Waiting List. <i>Hepatology</i> , 2020, 71, 1766-1774.	7.3	40
32	Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation. <i>Hepatology</i> , 2020, 71, 1775-1786.	7.3	15
33	Living Donor Liver Transplantation When Deceased Donor Is Not Possible or Timely: Case Examples and Ethical Perspectives. <i>Liver Transplantation</i> , 2020, 26, 431-436.	2.4	9
34	Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus. <i>Hepatology</i> , 2020, 72, 569-583.	7.3	45
35	A Comprehensive Review of Outcome Predictors in Low MELD Patients. <i>Transplantation</i> , 2020, 104, 242-250.	1.0	19
36	Patients With Persistently Low MELD-Na Scores Continue to Be at Risk of Liver-related Death. <i>Transplantation</i> , 2020, 104, 1413-1418.	1.0	26

#	ARTICLE	IF	CITATIONS
37	Kidney Failure Associates With T Cell Exhaustion and Imbalanced Follicular Helper T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 583702.	4.8	46
38	Prevention and Management of HBV in Organ Transplantation. <i>Current Hepatology Reports</i> , 2020, 19, 266-275.	0.9	0
39	In-Person Outreach and Telemedicine in Liver and Intestinal Transplant: A Survey of National Practices, Impact of Coronavirus Disease 2019, and Areas of Opportunity. <i>Liver Transplantation</i> , 2020, 26, 1354-1358.	2.4	22
40	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	6.1	55
41	Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 2173-2183.	4.7	30
42	The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. <i>Hepatology</i> , 2020, 72, 1127-1138.	7.3	29
43	Reply. <i>Liver Transplantation</i> , 2020, 26, 1068-1068.	2.4	0
44	Donor-Specific Antibodies in Liver Transplantation. <i>Clinical Liver Disease</i> , 2020, 15, 13-16.	2.1	12
45	Liver-related mortality is similar among men and women with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1072-1081.	3.7	16
46	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	4.3	9
47	Does the Liver Provide Immunosuppressive Advantage?. <i>Clinical Liver Disease</i> , 2019, 13, 180-183.	2.1	16
48	Too Much or Not Enough? Induction Immunosuppression in the Simultaneous Liver-Kidney Recipient. <i>Liver Transplantation</i> , 2019, 25, 365-366.	2.4	1
49	External Validation of a Pretransplant Biomarker Model (REVERSE) Predictive of Renal Recovery After Liver Transplantation. <i>Hepatology</i> , 2019, 70, 1349-1359.	7.3	17
50	Immunosuppressive Drug Levels in Liver Transplant Recipients: Impact in Decision Making. <i>Seminars in Liver Disease</i> , 2019, 39, 414-421.	3.6	5
51	Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1778-1780.	6.1	1
52	Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. <i>Hepatology</i> , 2019, 69, 1273-1286.	7.3	52
53	Age and liver transplantation. <i>Journal of Hepatology</i> , 2019, 70, 745-758.	3.7	186
54	A Model for Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) in the Presence of Renal Dysfunction[Link]. <i>Hepatology</i> , 2019, 69, 1219-1230.	7.3	47

#	ARTICLE	IF	CITATIONS
55	Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1397-1409.	4.7	103
56	A comprehensive pipeline for translational top-down proteomics from a single blood draw. <i>Nature Protocols</i> , 2019, 14, 119-152.	12.0	62
57	Transplanting livers from HCV infected donors into HCV negative recipients: Promise but mind the pitfalls. <i>American Journal of Transplantation</i> , 2019, 19, 1264-1265.	4.7	2
58	Paediatric to adult liver transition services: the state of play in the UK. <i>Clinical Medicine</i> , 2019, 19, 425-426.	1.9	12
59	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018, 102, 727-743.	1.0	178
60	Frailty after liver transplantation: The strong survive but may not prosper. <i>American Journal of Transplantation</i> , 2018, 18, 1841-1842.	4.7	2
61	Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 257-263.	1.6	15
62	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , 2018, 8, 3199.	3.3	18
63	Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 1096-1107.	1.0	26
64	Tolerance in clinical liver transplantation. <i>Human Immunology</i> , 2018, 79, 283-287.	2.4	69
65	The prevalence, risk factors, and outcomes of medication trade-offs in kidney and liver transplant recipients: a pilot study. <i>Transplant International</i> , 2018, 31, 870-879.	1.6	25
66	Donor-derived Viral Infections in Liver Transplantation. <i>Transplantation</i> , 2018, 102, 1824-1836.	1.0	17
67	Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. <i>American Journal of Transplantation</i> , 2018, 18, 2506-2512.	4.7	29
68	Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 182-190.	0.5	2
69	Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-3279.	3.6	24
70	Phosphatidylethanol Detects Moderate to Heavy Alcohol Use in Liver Transplant Recipients. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 857-862.	2.4	60
71	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV TARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	7.3	149
72	Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. <i>Journal of Hepatology</i> , 2017, 67, 517-525.	3.7	31

#	ARTICLE	IF	CITATIONS
73	Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. <i>Transplantation</i> , 2017, 101, 1056-1066.	1.0	15
74	Comprehensive Review on Colorectal Cancer and Transplant. <i>American Journal of Transplantation</i> , 2017, 17, 2761-2774.	4.7	18
75	Proteoforms in Peripheral Blood Mononuclear Cells as Novel Rejection Biomarkers in Liver Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2458-2467.	4.7	37
76	The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 2790-2802.	4.7	281
77	Reply. <i>Hepatology</i> , 2017, 66, 2089-2090.	7.3	0
78	A point-of-care based prediction model for cardiovascular risk in orthotopic liver transplantation: The CARa-COLT score. <i>Hepatology</i> , 2017, 66, 1968-1979.	7.3	82
79	Follow-up of the Post-Liver Transplantation Patient. <i>Clinics in Liver Disease</i> , 2017, 21, 793-813.	2.1	9
80	Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis. <i>Transplantation Direct</i> , 2017, 3, e188.	1.6	12
81	Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 584-593.e2.	4.4	162
82	Medication nonadherence in liver transplantation. <i>Clinical Liver Disease</i> , 2017, 10, 157-160.	2.1	3
83	Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. <i>PLoS ONE</i> , 2016, 11, e0156535.	2.5	11
84	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 2816-2835.	4.7	451
85	The impact of coronary artery disease on outcomes after liver transplantation. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 875-885.	1.5	42
86	Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. <i>American Journal of Transplantation</i> , 2016, 16, 2684-2694.	4.7	130
87	Mechanisms and Strategies for Tolerance in Liver Transplantation. <i>Current Transplantation Reports</i> , 2016, 3, 325-333.	2.0	0
88	Infection and Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 595-606.	2.1	33
89	Use of Six-Minute Walk Test to Measure Functional Capacity After Liver Transplantation. <i>Physical Therapy</i> , 2016, 96, 1456-1467.	2.4	23
90	Perioperative Ledipasvir+Sofosbuvir for HCV in Liver-Transplant Recipients. <i>New England Journal of Medicine</i> , 2016, 375, 2106-2108.	27.0	77

#	ARTICLE	IF	CITATIONS
91	Liver Websites. Transplantation, 2016, 100, 1594.	1.0	0
92	Inpatient Hypoglycemic Events in a Comparative Effectiveness Trial for Glycemic Control in a High-Risk Population. Endocrine Practice, 2016, 22, 1040-1047.	2.1	6
93	The utility of pulmonary function testing in predicting outcomes following liver transplantation. Liver Transplantation, 2016, 22, 805-811.	2.4	23
94	Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin. Human Immunology, 2016, 77, 367-374.	2.4	7
95	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology, 2016, 64, 717-735.	3.7	243
96	Ethical Considerations of Transplantation and Living Donation for Patients with Alcoholic Liver Diseases. AMA Journal of Ethics, 2016, 18, 163-173.	0.7	15
97	National survey of adult transplant hepatologists on the pediatric-to-adult care transition after liver transplantation. Liver Transplantation, 2015, 21, 213-223.	2.4	45
98	Simulation Modeling of the Impact of Proposed New Simultaneous Liver and Kidney Transplantation Policies. Transplantation, 2015, 99, 424-430.	1.0	20
99	Keeping high model for end-stage liver disease score liver transplantation candidates alive. Liver Transplantation, 2015, 21, 1428-1437.	2.4	12
100	Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. Transplantation, 2015, 99, 1644-1651.	1.0	19
101	Constrictive Pericarditis as a Cause of Refractory Ascites. ACG Case Reports Journal, 2015, 2, 175-177.	0.4	5
102	Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transplantation, 2015, 21, 22-28.	2.4	74
103	Incidence and impact of rejection following simultaneous liver-kidney transplantation. Journal of Hepatology, 2015, 62, 340-345.	3.7	20
104	Solid Organ Transplantation From Hepatitis B Virus-Positive Donors: Consensus Guidelines for Recipient Management. American Journal of Transplantation, 2015, 15, 1162-1172.	4.7	196
105	Reply. Liver Transplantation, 2014, 20, 499-499.	2.4	0
106	Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology, 2014, 60, 2017-2026.	7.3	50
107	An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine, 2014, 371, 2375-2382.	27.0	377
108	Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transplantation, 2014, 20, 1034-1044.	2.4	20

#	ARTICLE	IF	CITATIONS
109	High early cardiovascular mortality after liver transplantation. Liver Transplantation, 2014, 20, 1306-1316.	2.4	154
110	OR26. Human Immunology, 2014, 75, 21.	2.4	0
111	New models to enhance the assessment of mortality risk in low model for end-stage liver disease patients: "Objectifying" the subjective. Liver Transplantation, 2014, 20, 1153-1154.	2.4	0
112	A meta-analysis of complications following deceased donor liver transplant. American Journal of Surgery, 2014, 208, 605-618.	1.8	27
113	The Current State and Future Prospects of Chronic Hepatitis C Virus Infection Treatment. Current Infectious Disease Reports, 2014, 16, 413.	3.0	8
114	Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology, 2013, 57, 239-248.	7.3	52
115	Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients. Clinics in Liver Disease, 2013, 17, 737-747.	2.1	8
116	National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transplantation, 2013, 19, 395-403.	2.4	57
117	Genomic Biomarkers Correlate with HLA-Identical Renal Transplant Tolerance. Journal of the American Society of Nephrology: JASN, 2013, 24, 1376-1385.	6.1	60
118	Donor and recipient effects on graft and patient survival. Clinical Liver Disease, 2013, 2, 152-155.	2.1	3
119	Find it in your heart. Liver Transplantation, 2013, 19, 567-568.	2.4	0
120	Immunosuppression withdrawal following liver transplantation: The older, the wiser – but maybe too late. Hepatology, 2013, 58, 1529-1532.	7.3	8
121	Inhibitory Effects of Belatacept on Allospecific Regulatory T-Cell Generation in Humans. Transplantation, 2013, 96, 689-696.	1.0	37
122	MRI-guided Biopsy to Correlate Tissue Specimens with MR Elastography Stiffness Readings in Liver Transplants. Academic Radiology, 2012, 19, 1121-1126.	2.5	18
123	40-OR. Human Immunology, 2012, 73, 33.	2.4	0
124	Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Human Immunology, 2012, 73, 141-149.	2.4	19
125	Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon. Gastroenterology, 2012, 142, 1132-1139.e1.	1.3	104
126	To kidney or not to kidney, when "is" is the question. Liver Transplantation, 2012, 18, 875-877.	2.4	0

#	ARTICLE	IF	CITATIONS
127	Assessment of Chronic Hepatitis and Fibrosis: Comparison of MR Elastography and Diffusion-Weighted Imaging. <i>American Journal of Roentgenology</i> , 2011, 196, 553-561.	2.2	198
128	Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. <i>Transplantation</i> , 2011, 91, 199-206.	1.0	34
129	Magnetic Resonance Elastography and Biomarkers to Assess Fibrosis From Recurrent Hepatitis C in Liver Transplant Recipients. <i>Transplantation</i> , 2011, 92, 581-586.	1.0	57
130	Haploidentical hematopoietic stem cell transplantation for graft-versus-host disease after liver transplantation. <i>Blood</i> , 2011, 118, 3448-3449.	1.4	8
131	Glycemic Control by A Glucose Management Service and Infection Rates After Liver Transplantation. <i>Endocrine Practice</i> , 2011, 17, 546-551.	2.1	37
132	The renal benefit of mycophenolate mofetil after liver transplantation. <i>Clinical Transplantation</i> , 2011, 25, E88-E95.	1.6	11
133	Mycophenolate mofetil monotherapy in liver transplant recipients. <i>Clinical Transplantation</i> , 2011, 25, E639-E646.	1.6	7
134	Chronic rejection related to hepatitis B immunoglobulin discontinuation in a liver transplant recipient. <i>Transplant International</i> , 2011, 24, e104-e106.	1.6	6
135	Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 32-37.	2.4	34
136	Operational tolerance: Past lessons and future prospects. <i>Liver Transplantation</i> , 2011, 17, 222-232.	2.4	72
137	Association of hepatic artery stenosis and biliary strictures in liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 849-854.	2.4	51
138	Next level of immunosuppression: Drug/immune monitoring. <i>Liver Transplantation</i> , 2011, 17, S60-S65.	2.4	16
139	Requirement of Cognate CD4+ T-Cell Recognition for the Regulation of Allo-specific CTL by Human CD4+CD127 <sup>hi</sup> CD25+FOXP3+ Cells Generated in MLR. <i>PLoS ONE</i> , 2011, 6, e22450.	2.5	3
140	Posttransplant Hyperglycemia is Associated With Increased Risk of Liver Allograft Rejection. <i>Transplantation</i> , 2010, 89, 222-226.	1.0	76
141	Transjugular Intrahepatic Portosystemic Shunt with Thrombectomy for the Treatment of Portal Vein Thrombosis After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 529-534.	2.3	19
142	Evaluation of the coagulation and inflammatory responses in solid organ transplant recipients and donors. <i>Clinical Transplantation</i> , 2009, 23, 943-950.	1.6	16
143	Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. <i>Human Immunology</i> , 2009, 70, 146-150.	2.4	29
144	Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. <i>Journal of Hepatology</i> , 2009, 51, 874-880.	3.7	34

#	ARTICLE	IF	CITATIONS
145	Overview of immunosuppression in liver transplantation. World Journal of Gastroenterology, 2009, 15, 4225.	3.3	102
146	The Human $\alpha$ Treg MLR: Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation, 2009, 88, 1303-1311.	1.0	36
147	Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?. Clinical Transplantation, 2008, 22, 222-228.	1.6	24
148	A Survey of CMV Prevention Strategies After Liver Transplantation. American Journal of Transplantation, 2008, 8, 158-161.	4.7	86
149	Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transplantation, 2008, 14, 1498-1504.	2.4	83
150	Herpes simplex virus hepatitis: An analysis of the published literature and institutional cases. Liver Transplantation, 2007, 13, 1428-1434.	2.4	229
151	Hepatic complications of hematopoietic cell transplantation. Current Gastroenterology Reports, 2007, 9, 60-65.	2.5	29
152	Acid-Base and Potassium Disorders in Liver Disease. Seminars in Nephrology, 2006, 26, 466-470.	1.6	46
153	Probiotics: Application of $\alpha$ healthy $\alpha$ bacteria to liver transplant recipients. Hepatology, 2006, 44, 507-510.	7.3	5
154	The liver transplant recipient: what you need to know for long-term care. Journal of Family Practice, 2006, 55, 136-44.	0.2	7
155	Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. Annals of Internal Medicine, 2005, 143, 870.	3.9	344
156	Herpes zoster infection after liver transplantation: A case-control study. Liver Transplantation, 2005, 11, 320-325.	2.4	35
157	Chicken pox after pediatric liver transplantation. Liver Transplantation, 2005, 11, 1563-1566.	2.4	22
158	A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy. Diseases of the Colon and Rectum, 2005, 48, 1-8.	1.3	78
159	Fulminant Liver Failure Associated with the Use of Black Cohosh. Digestive Diseases and Sciences, 2005, 50, 538-539.	2.3	73
160	Operative Risk of Total Hip and Knee Arthroplasty in Cirrhotic Patients. Journal of Arthroplasty, 2005, 20, 460-466.	3.1	76
161	Diagnosis and Therapy of Alcoholic Liver Disease. Seminars in Liver Disease, 2004, 24, 233-247.	3.6	101
162	The safety and outcome of joint replacement surgery in liver transplant recipients. Liver Transplantation, 2003, 9, 373-376.	2.4	37

#	ARTICLE	IF	CITATIONS
163	The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 733-736.	2.4	52
164	Oral Vitamin A Therapy for a Patient With a Severely Symptomatic Postradiation Anal Ulceration. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 679-682.	1.3	9
165	The natural history and outcome of large bowel dysplasia and cancer in patients with Crohn's colitis. <i>Gastroenterology</i> , 2003, 124, A211.	1.3	0
166	Oral vitamin A for the treatment of chronic radiation proctopathy: A randomized, controlled trial. <i>Gastroenterology</i> , 2003, 124, A64.	1.3	0
167	Crohn's Disease and Takayasu's Arteritis. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 454-456.	2.2	22
168	Varicella Infection Following Varicella Vaccination in a Liver Transplant Recipient. <i>American Journal of Transplantation</i> , 2002, 2, 880-882.	4.7	50
169	Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 572-572.	2.4	9
170	Sodium Ion/Hydrogen Ion Exchange Inhibition: A New Pharmacologic Approach to Myocardial Ischemia and Reperfusion Injury. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 887-897.	2.0	69